• 1
    Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: Management of Hepatitis C: 2002. Hepatology 2002; 36 (Suppl 1): 0S12.
  • 2
    Herrine SK. Approach to the patient with chronic hepatitis C virus infection. Ann Intern Med 2002; 136: 74757.
  • 3
    Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 22: 95865.
  • 4
    Fried MW, Schiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 5
    Dieterich DT, Spivak JL. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003; 15: 53341.
  • 6
    Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26(3 Suppl 1): 11221S.
  • 7
    Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002; 123: 14151.
  • 8
    Peck-Radosavljevic M, Wichlas M, Pidlich J et al. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998; 28: 14249.
  • 9
    Fattorutto M, Pradier O, Schmartz D, Ickx B, Barvais L. Does the platelet function analyser (PFA-100) predict blood loss after cardiopulmonary bypass? Br J Anaesth 2003; 90: 6923.
  • 10
    Blanchette VS, Sparling C, Turner C. Inherited bleeding disorders. Baillieres Clin Hematol 1991; 4: 291332.
  • 11
    Westerhout CM, Boersma E. Risk-benefit analysis of platelet glycoprotein inhibitors in acute coronary syndromes. Expert Opin Drug Saf 2003; 2: 4958.
  • 12
    Harrison P, Robinson MS, Mackie IJ, et al. Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinolysis 1999; 10: 2531.
  • 13
    Harrison P, Robinson M Liesner R, et al. The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction. Clin Lab Hematol 2002; 24: 22532.
  • 14
    Eckman MH, Erban JK, Singh SK, Kao GS. Screening for the risk for bleeding or thrombosis. Ann Intern Med 2003; 138: 1524.
  • 15
    Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138: 15263.
  • 16
    Cariappa R, Wilhite TR, Parvin CA, Luchtman-Jones L. Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems. J Pediatr Hematol Oncol 2003; 25: 4749.
  • 17
    Troost MM, van Genderen PJ. Excessive prolongation of the Ivy bleeding time after aspirin in essential thrombocythemia is also demonstrable in vitro in the high shear stress system PFA-100. Ann Hematol 2002; 81: 3534.
  • 18
    Zaccaria F, Dietrich W, Richter JA. In vitro bleeding time (PFA-100TM) helps to identify patients with platelet dysfuction-dependent increased bleeding after coronary artery bypass grafting. Critical Care 2003; 7(Suppl 1): 12.
  • 19
    Favaloro EJ, Facey D, Henniker A. Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders. Am J Hematol 1999; 62: 16574.
  • 20
    Homoncik M, Blann AD, Hollenstein U, Pernerstorfer T, Eichler HG, Jilma B. Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol 2000; 111: 12502.
  • 21
    Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors. A dual role for glycoprotein IIb-IIIa (integrin alpha IIb beta 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J Biol Chem 1992; 267: 113006.
  • 22
    Berndt MC, Shen Y, Dopheide SM, Gardiner EE, Andrews RK. The vascular biology of the glycoprotein Ib-IX-V complex. Thromb Haemost 2001; 86: 17888.
  • 23
    Ferenci P, Michael G, Laferl H, et al. Prospective evaluation of the 24 hour interferon-induced decline in hepatitis C virus genotype I load to predict response to peginterferon-alfa2a/ribavirin combination therapy. Gastroenterology 2003; 124 (Suppl 1): A767.
  • 24
    Rand ML, Carcao MD, Blanchette VS. Use of the PFA-100 in the assessment of primary, platelet-related hemostasis in a pediatric setting. Semin Thromb Hemost 1998; 24: 5239.
  • 25
    Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000; 83: 31621.
  • 26
    De La Cadena RA, Majluf-Cruz A, Stadnicki A, et al. Recombinant tumor necrosis factor receptor p75 fusion protein (TNFR:Fc) alters endotoxin-induced activation of the kinin, fibrinolytic, and coagulation systems in normal humans. Thromb Haemost 1998; 80: 1148.
  • 27
    Kreil A, Kobryn T, Wichlas M, et al. TNF-alpha, its soluble receptors and HCV kinetics during IFN-Induction therapy. Gastroenterology 2002; 123 (Suppl 1): 77.
  • 28
    Reiter RA, Mayr F, Blazicek H, et al. Desmopressin and platelets antagonize the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003; 102: 45949.
  • 29
    Mazzucconi MG, Ferrari A, Solinas S, et al. Studies of von Willebrand factor in essential thrombocythemia patients treated with alpha-2b recombinant interferon. Haemostasis 1991; 21: 13540.
  • 30
    Stevens TR, James JP, Simmonds NJ, et al. Circulating von Willebrand factor in inflammatory bowel disease. Gut 1992; 33: 5026.
  • 31
    Blann AD, Herrick A, Jayson MI. Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. Br J Rheumatol 1995; 34: 8149.
  • 32
    Ferro D, Quintarelli C, Lattuada A, et al. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 1996; 23: 137783.
  • 33
    Albornoz L, Alvarez D, Otaso JC, et al. Von Willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide levels. J Hepatol 1999; 30: 4515.
  • 34
    Beer JH, Clerici N, Baillod P, von Felten A, Schlappritzi E, Buchi L. Quantitative and qualitative analysis of platelet GPIb and von Willebrand factor in liver cirrhosis. Thromb Haemost 1995; 73: 6019.
  • 35
    Mannucci M, Canciani T, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98: 27305.
  • 36
    Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000; 95: 29839.
  • 37
    Homoncik M, Jilma-Stohlawetz P, Schmid M, Ferlitsch A, Peck-Radosavljevic M. Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis. A randomized, double blind, placebo controlled study. Aliment Pharmacol Ther 2004; 15: 43743.